Volume 32 Issue 4, April 2014

New mouse models of human immunity will enable a variety of research and clinical applications (p 335). Humanized mice described by Rongvaux et al. (p 364) can be used to study the influence of human immune cells on disease pathology and response to therapy. The mice presented by Lee et al. (p 356) may be used to evaluate the efficacy of candidate vaccines, and to rapidly produce human antibodies having high affinity for therapeutic targets. Credit: © tiripero iStock.

Editorial

Genome editing for all

CRISPR-Cas is about to transform how we interrogate genetic variants and model disease.

Editorial 08 Apr 2014

Advertisement

Top of page ⤴

News

Immune-checkpoint inhibitors march on, now in combinations

Cormac Sheridan
News 08 Apr 2014
Ablynx checkpoint agents lure Merck

Gunjan Sinha
News 08 Apr 2014
Mitochondrial medicine

Emma Dorey
News 08 Apr 2014
Leptin therapy gains FDA approval

Gunjan Sinha
News 08 Apr 2014
Epilepsy neurodevice approved

Alli Proffitt
News 08 Apr 2014
AAV gene therapy continues to woo investors

Barbara Cassasus
News 08 Apr 2014
Cheerios alert

News 08 Apr 2014
Circadian rhythm drug approved

Man Tsuey Tse
News 08 Apr 2014
Engineered tracheas, corneas and arteries enter clinical testing

Michael Eisenstein
News 08 Apr 2014
Fraunhofer to mine Sanofi microbial collection

Jeffrey L Fox
News 08 Apr 2014
First royal to have genome sequenced

News 08 Apr 2014
Cancer trial assesses clinical benefit of gene-targeted treatment

Alla Katsnelson
News 08 Apr 2014
Ten large companies join NIH to speed up drug discovery

Jeffrey L Fox
News 08 Apr 2014
Around the world in a month

News 08 Apr 2014

Top of page ⤴

Data Page

Drought-tolerant varieties begin global march

Andrew Marshall
Data Page 08 Apr 2014

Top of page ⤴

News Feature

Gene editing at CRISPR speed

Ease of use, economy and speed of targeting DNA has propelled the CRISPR-Cas system into the spotlight. Now, despite numerous gaps in our knowledge, commercial entities are looking for a piece of the action. Monya Baker reports.

News Feature 08 Apr 2014

Top of page ⤴

Bioentrepreneur

Academic-industry partnerships 2013

Brady Huggett
Bioentrepreneur 08 Apr 2014
First Rounders: Michael West

Bioentrepreneur 08 Apr 2014

Top of page ⤴

Correspondence

HIV eradication—from Berlin to Boston

Paula M Cannon
Donald B Kohn
Hans-Peter Kiem
Correspondence 08 Apr 2014
The time is ripe for an ethics of entrepreneurship

Christopher Thomas Scott
Emily L Borgelt
Sandra Soo-Jin Lee
Correspondence 08 Apr 2014
The third way of umbilical cord blood banking

Hung-Chieh Chang
Correspondence 08 Apr 2014
The morality of patents on pre-implantation genetic diagnosis

David B Resnik
Correspondence 08 Apr 2014
Putting cells to sleep for future science

Glyn N Stacey
John G Day
Correspondence 08 Apr 2014

Top of page ⤴

Feature

A survey of breakthrough therapy designations

As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration—drugs against cancer, hepatitis C and monogenetic diseases predominate.

Saurabh (Rob) Aggarwal
Feature 08 Apr 2014

Top of page ⤴

Patents

Does CRISPR-Cas open new possibilities for patents or present a moral maze?

CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.

Philip Webber
Patents 08 Apr 2014
Recent patent applications in CRISPR-Cas systems

Patents 08 Apr 2014

Top of page ⤴

News & Views

New models of human immunity

Two humanized mouse models open up a plethora of research applications.

Hergen Spits
News & Views 08 Apr 2014
Making light of stress

A nanoparticle that senses reactive oxygen and nitrogen species in the liver should improve in vivo detection of cellular stress.

Jefferson Chan
Christopher J Chang
News & Views 08 Apr 2014
Cas9 in close-up

Structural and biochemical studies elucidate DNA targeting by the Cas9 endonuclease.

Erin L Garside
Andrew M MacMillan
News & Views 08 Apr 2014
Research Highlights

News & Views 08 Apr 2014

Top of page ⤴

Analysis

Genome-guided transcript assembly by integrative analysis of RNA sequence data

Boley et al. describe an automated approach for integrating multiple types of RNA sequence data to assemble transcripts.

Nathan Boley
Marcus H Stoiber
James B Brown
Analysis 16 Mar 2014

Top of page ⤴

Review Article

CRISPR-Cas systems for editing, regulating and targeting genomes

Jeffry D Sander
J Keith Joung
Review Article 02 Mar 2014

Top of page ⤴

Article

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

Mice engineered to express the entire human variable immunoglobulin region enable rapid isolation of high-affinity antibodies specific for antigens of interest.

E-Chiang Lee
Qi Liang
Allan Bradley
Article 16 Mar 2014
Development and function of human innate immune cells in a humanized mouse model

A mouse bearing multiple human cytokine genes enables in vivo development and function of various human innate immune cell types.

Anthony Rongvaux
Tim Willinger
Richard A Flavell
Article 16 Mar 2014
Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing

Semiconducting polymer nanoparticles are used to image toxic reactive oxygen and reactive nitrogen species in live mice.

Adam J Shuhendler
Kanyi Pu
Jianghong Rao
Article 23 Mar 2014

Top of page ⤴

Letter

The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells

An algorithm uncovers transcriptome dynamics during differentiation by ordering RNA-Seq data from single cells.

Cole Trapnell
Davide Cacchiarelli
John L Rinn
Letter 23 Mar 2014
Massively parallel functional annotation of 3′ untranslated regions

A method for high-throughput functional testing of 3′ UTR sequences uncovers new regulatory elements and effects of noncoding genetic variants.

Wenxue Zhao
Joshua L Pollack
David J Erle
Letter 16 Mar 2014

Top of page ⤴

Careers and Recruitment

Pay increases still healthy for nonfounder executives at private life sciences companies

Executive cash compensation data for nonfounders revealed a 3% year-over-year rise.

Bruce Rychlik
Careers and Recruitment 08 Apr 2014
People

Careers and Recruitment 08 Apr 2014

Top of page ⤴

Volume 32 Issue 4, April 2014

Editorial

News

Data Page

News Feature

Bioentrepreneur

Correspondence

Feature

Patents

News & Views

Analysis

Review Article

Article

Letter

Careers and Recruitment

Search

Quick links